Peptides DB
Research-centric peptide and protocol reference hub
Study 15 of 15Evuzamitide literatureJAMATop journal2026

124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.

Not reported in abstract.

Read at JAMAAdd to compare

Where it sits

this study against the rest of the evuzamitide corpus
0
Preclinical
8
Observational
1
Open-label · this one
1
Randomised
5
Reviews

Summary and findings

Not reported in abstract.

How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Evuzamitide corpus

B124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.JAMA · 2026 · Overall sensitivity was 94% (95% CI, 85%-98%; P < 0.001).HumanB124Iodine Evuzamitide Positron Emission Tomography in Patients with Established or Suspected Cardiac Amyloidosis.JACC. Cardiovascular imaging · 2026 · Mean LV/blood pool standardized uptake value ratio (SUVRmean) was 1.89 ±0.29 in patients with CA and 0.91 ±0.15 in patients without CA, p<0.001.HumanDDiagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis.European heart journal. Imaging methods and practice · 2026 · Summary sensitivity of 0.91 (95% CI 0.83-0.96), n=577.reviewDDelivering the blueprint: Advances and challenges in mRNA therapeutics for the respiratory system.International journal of pharmaceutics: X · 2026reviewBPatient and clinician experiences of language barriers in Qatar's multilingual public mental health care: a qualitative study.International journal of qualitative studies on health and well-being · 2026HumanBAI-assisted MALDI-TOF MS for identifying carbapenem resistance in clinical Acinetobacter baumannii isolates.Emerging microbes & infections · 2026 · n=191 · Accuracy of 96.36% in distinguishing CRAB from CSAB.Human